Here are Surajit Pal's views on pharmaceutical space

In an interview to CNBC-TV18, Surajit Pal, Pharma Analyst at Prabhudas Lilladher shared his views and readings on the latest happenings in pharmaceutical space especially on Sun Pharmaceutical Industries and Aurobindo Pharma.

Palpable deficiencies are there in Sun Pharma because of macroeconomic scenario. The run up in Sun Pharma has come to an end and going forward Lupin and Mylan also will intensify competition in those products where Taro gets maximum benefits, he said.

I don’t see any improvement going forward and I am not in the camp to believe that this is the end of the downfall and after that everything will be smooth. I think worst is yet to come and it is very hard to predict when it will come, he added.

For full interview, watch accompanying video...